A Land of Controversy: Fibroblast Growth Factor-23 and Uremic Cardiac Hypertrophy

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Cardiac hypertrophy is prevalent in chronic kidney disease (CKD).
• Fibroblast growth factor-23 (FGF23) and α-Klotho are key phosphate regulators implicated in CKD pathophysiology.
• Altered FGF23 and α-Klotho levels may contribute to cardiac hypertrophy through direct cardiac effects or systemic changes.

Purpose of the Study:

• To review the cardiac effects of the FGF23/α-Klotho axis in CKD.
• To summarize recent research progress in this area.
• To present and address controversies regarding the FGF23/α-Klotho axis and cardiac hypertrophy.

Main Methods:

• Literature review of studies investigating the FGF23/α-Klotho axis and cardiac hypertrophy in CKD.
• Analysis of conflicting findings and proposed mechanisms.
• Synthesis of current evidence and identification of research gaps.

Main Results:

• The FGF23/α-Klotho axis plays a significant role in CKD-induced cardiac hypertrophy.
• Evidence suggests FGF23 and α-Klotho influence cardiac structure and function.
• Contradictory findings exist regarding the direct causal link between FGF23/α-Klotho axis disturbances and cardiac hypertrophy.

Conclusions:

• The FGF23/α-Klotho axis is a critical factor in CKD-related cardiac hypertrophy, though its precise role is debated.
• Further research is needed to reconcile conflicting data and clarify the mechanisms involved.
• Understanding this axis may reveal novel therapeutic targets for managing cardiac complications in CKD.